Skip NavigationSkip to Content

Insulin suppresses transactivation by CAAT/enhancer-binding proteins beta (C/EBP beta) - Signaling to p300/CREB-binding protein by protein kinase B disrupts interaction with the major activation domain of C/EBP beta

  1. Author:
    Guo, S. D.
    Cichy, S. B.
    He, X. W.
    Yang, Q. Y.
    Ragl, M.
    Ghosh, A. K.
    Johnson, P. F.
    Unterman, T. G.
  2. Author Address

    Vet Affairs Chicago Hlth Care Syst W Side, Rm 5A122A Res MP 151, 820 S Damen Ave, Chicago, IL 60612 USA. Univ Illinois, Coll Med, Chicago, IL 60612 USA. Res Genet Inc, Huntsville, AL 35801 USA. NCI, Eukaryot Transcript Regulat Sect, Regulat Cell Growth Lab, Frederick Canc Res & Dev Ctr, Bethesda, MD 20892 USA. Unterman TG Vet Affairs Chicago Hlth Care Syst W Side, Rm 5A122A Res MP 151, 820 S Damen Ave, Chicago, IL 60612 USA.
    1. Year: 2001
  1. Journal: Journal of Biological Chemistry
    1. 276
    2. 11
    3. Pages: 8516-8523
  2. Type of Article: Article
  1. Abstract:

    CAAT/enhancer-binding proteins (C/EBPs) play an important role in the regulation of gene expression in insulin-responsive tissues. We have found that a complex containing C/EBP beta interacts with an insulin response sequence in the insulin-like growth factor-binding protein-1 (IGFBP-1) gene and that a C/EBP-binding site can mediate effects of insulin on promoter activity. Here, we examined mechanisms mediating this effect of insulin. The ability of insulin to suppress promoter activity via a C/EBP-binding site is blocked by LY294002, a phosphatidylinositol 3-kinase inhibitor, but not by rapamycin, which blocks activation of p70(S6 kinase). Dominant negative phosphatidylinositol 3-kinase and protein kinase B (PKB) block the effect of insulin, while activated PKB suppresses promoter function via a C/EBP-binding site, mimicking the effect of insulin, Coexpression studies indicate that insulin and PKB suppress transactivation by C/EBP beta, but not C/EBP alpha, and that N-terminal transactivation domains in C/EBP beta are required. Studies with Gal4 fusion proteins reveal that insulin and PKB suppress transactivation by the major activation domain in C/EBP beta (AD II), located between amino acids 31 and 83, Studies with E1A protein indicate that interaction with p300/CBP is required for transactivation by AD II and the effect of insulin and PKB, Based on a consensus sequence, we identified a PKB phosphorylation site (Ser(1834)) within the region of p300/CBP known to bind C/EBP beta, Mammalian two- hybrid studies indicate that insulin and PKB disrupt interactions between this region of p300 and AD II and that Ser(1834) is critical for this effect. Signaling by PKB and phosphorylation of Ser(1834) may play an important role in modulating interactions between p300/CBP and transcription factors and mediate effects of insulin and related growth factors on gene expression.

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel